NO20062676L - Substituerte triazoler som natriumkanalblokkere - Google Patents

Substituerte triazoler som natriumkanalblokkere

Info

Publication number
NO20062676L
NO20062676L NO20062676A NO20062676A NO20062676L NO 20062676 L NO20062676 L NO 20062676L NO 20062676 A NO20062676 A NO 20062676A NO 20062676 A NO20062676 A NO 20062676A NO 20062676 L NO20062676 L NO 20062676L
Authority
NO
Norway
Prior art keywords
pain
alone
pharmaceutically acceptable
effective amount
compounds
Prior art date
Application number
NO20062676A
Other languages
English (en)
Norwegian (no)
Inventor
Prasun K Chakravarty
Williams H Parsons
Michael H Fisher
Hyun Ok
Brenda Palucki
Min K Park
Bishan Zhou
Edward Gonzalez
Rosemary Sisco
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of NO20062676L publication Critical patent/NO20062676L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Anesthesiology (AREA)
  • Immunology (AREA)
  • AIDS & HIV (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Biotechnology (AREA)
NO20062676A 2003-11-10 2006-06-09 Substituerte triazoler som natriumkanalblokkere NO20062676L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51889003P 2003-11-10 2003-11-10
PCT/US2004/037280 WO2005047270A2 (fr) 2003-11-10 2004-11-05 Triazoles substitues utilises en tant que bloqueurs du canal sodique

Publications (1)

Publication Number Publication Date
NO20062676L true NO20062676L (no) 2006-08-10

Family

ID=34590316

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20062676A NO20062676L (no) 2003-11-10 2006-06-09 Substituerte triazoler som natriumkanalblokkere

Country Status (17)

Country Link
US (2) US20090074890A1 (fr)
EP (1) EP1694654B1 (fr)
JP (1) JP2007510741A (fr)
KR (1) KR20060123739A (fr)
CN (1) CN1922156A (fr)
AT (1) ATE500234T1 (fr)
AU (1) AU2004289694B2 (fr)
BR (1) BRPI0416319A (fr)
CA (1) CA2545254A1 (fr)
DE (1) DE602004031667D1 (fr)
IL (1) IL175522A0 (fr)
IS (1) IS8438A (fr)
NO (1) NO20062676L (fr)
NZ (1) NZ547044A (fr)
RU (1) RU2372339C2 (fr)
WO (1) WO2005047270A2 (fr)
ZA (1) ZA200603583B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY142651A (en) * 2003-03-18 2010-12-15 Merck Sharp & Dohme Biaryl substituted triazoles as sodium channel blockers
BRPI0416319A (pt) * 2003-11-10 2007-01-09 Merck & Co Inc composto, composição farmacêutica, métodos de tratamento ou prevenção da dor, das sìndromes, e de doença, e, métodos de administrar anestesia local, e para a neuroproteção sob condições isquêmicas
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
GB0603008D0 (en) * 2006-02-14 2006-03-29 Portela & Ca Sa Method
KR100808551B1 (ko) 2006-12-01 2008-03-03 한국생명공학연구원 트리아졸 유도체를 유효성분으로 함유하는 대사성 질환 예방 및 치료용 약학적 조성물
DK2118077T3 (en) 2007-02-08 2015-03-09 Synta Pharmaceuticals Corp Triazole compounds that modulate HSP90 ACTIVITY
EP2129225B1 (fr) * 2007-04-03 2012-12-05 E. I. Du Pont de Nemours and Company Fongicides contenant du benzene substitue
JP5613565B2 (ja) * 2007-10-25 2014-10-22 リバルシオ コーポレイション 細胞膜媒介細胞内シグナル伝達を調節するための組成物および方法
EP2207669A4 (fr) * 2007-10-25 2011-11-02 Revalesio Corp Compositions bactériostatiques ou bactériocides et procédés
WO2009067621A1 (fr) 2007-11-21 2009-05-28 Decode Genetics Ehf Inhibiteurs de biaryle pde4 pour le traitement de troubles pulmonaires et cardiovasculaires
EP2222638A2 (fr) * 2007-11-21 2010-09-01 Decode Genetics EHF Inhibiteurs de pde4 biaryle pour traiter une inflammation
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
JP2013518085A (ja) 2010-02-01 2013-05-20 ノバルティス アーゲー ＣＲＦ−１受容体アンタゴニストとしてのピラゾロ［５，１ｂ］オキサゾール誘導体
WO2011092293A2 (fr) 2010-02-01 2011-08-04 Novartis Ag Dérivés de cyclohexylamide utilisés en tant qu'antagonistes du récepteur du crf
ES2527849T3 (es) 2010-02-02 2015-01-30 Novartis Ag Derivados de ciclohexilamida como antagonistas del receptor de CRF
AR086554A1 (es) 2011-05-27 2014-01-08 Novartis Ag Derivados de la piperidina 3-espirociclica como agonistas de receptores de la ghrelina
EP2852591A1 (fr) 2012-05-03 2015-04-01 Novartis AG Sel de l-malate de dérivés de 2,7-diaza-spiro[4.5]déc-7-yle et ses formes cristallines à titre d'agonistes des récepteurs de ghreline

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19816880A1 (de) * 1998-04-17 1999-10-21 Boehringer Ingelheim Pharma Neue Diphenyl-substituierte 5-Ring-Heterocyclen, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel
AR029489A1 (es) * 2000-03-10 2003-07-02 Euro Celtique Sa Piridinas, pirimidinas, pirazinas, triazinas sustituidas por arilo, composiciones farmaceuticas y el uso de las mismas para la manufactura de un medicamento
AU4589701A (en) * 2000-03-24 2001-10-08 Cocensys Inc Aryl substituted pyrazoles, triazoles and tetrazoles, and the use thereof
AR037233A1 (es) * 2001-09-07 2004-11-03 Euro Celtique Sa Piridinas aril sustituidas, composiciones farmaceuticas y el uso de dichos compuestos para la elaboracion de un medicamento
US20060183897A1 (en) * 2003-03-18 2006-08-17 Chakravarty Prasun K Biaryl substituted triazoles as sodium channel blockers
MY142651A (en) * 2003-03-18 2010-12-15 Merck Sharp & Dohme Biaryl substituted triazoles as sodium channel blockers
BRPI0416319A (pt) * 2003-11-10 2007-01-09 Merck & Co Inc composto, composição farmacêutica, métodos de tratamento ou prevenção da dor, das sìndromes, e de doença, e, métodos de administrar anestesia local, e para a neuroproteção sob condições isquêmicas

Also Published As

Publication number Publication date
ATE500234T1 (de) 2011-03-15
IL175522A0 (en) 2006-09-05
IS8438A (is) 2006-05-04
US7459475B2 (en) 2008-12-02
JP2007510741A (ja) 2007-04-26
US20090074890A1 (en) 2009-03-19
KR20060123739A (ko) 2006-12-04
CN1922156A (zh) 2007-02-28
EP1694654B1 (fr) 2011-03-02
NZ547044A (en) 2010-05-28
AU2004289694A1 (en) 2005-05-26
US20060020006A1 (en) 2006-01-26
RU2372339C2 (ru) 2009-11-10
EP1694654A2 (fr) 2006-08-30
CA2545254A1 (fr) 2005-05-26
ZA200603583B (en) 2007-08-29
BRPI0416319A (pt) 2007-01-09
DE602004031667D1 (de) 2011-04-14
WO2005047270A3 (fr) 2005-09-22
WO2005047270A2 (fr) 2005-05-26
RU2006120426A (ru) 2007-12-27
AU2004289694B2 (en) 2010-05-13

Similar Documents

Publication Publication Date Title
NO20062676L (no) Substituerte triazoler som natriumkanalblokkere
JO2480B1 (en) Triple aryl substituted with aryl as a sodium channel blocking agent
ES2151599T3 (es) Acidos hidroxamicos substituidos con arilsulfonamido como inhibidores de matriz metaloproteinasas.
WO2007145922A3 (fr) Benzazépinones en tant que bloqueurs des canaux sodiques
WO2007075524A3 (fr) Pipéridines substituées en tant que bloqueurs des canaux calciques
WO2005030766A8 (fr) Composes phenyl-carboxamide utiles pour traiter la douleur
MXPA05009611A (es) Piperidinas sustituidas como nuevos inhibidores de mdm2-p53.
GEP20125389B (en) Substituted pyrazole and triazole compounds as ksp inhibitors
MY147188A (en) Substituted imidazole compounds as ksp inhibitors
WO2010115184A3 (fr) Hydroxylthiénoquinolones et composés apparentés utilisables en tant qu'agents anti-infectieux
WO2004011477A3 (fr) Ketolides pontes aux carbones 6,11-4
EA201071395A1 (ru) Ингибитор толерантности к анальгетику
WO2006009893A3 (fr) Chimiotherapie anticancereuse
TW200633710A (en) Triazole compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor
TW200714596A (en) Isotopically substituted proton pump inhibitors
WO2007047881A3 (fr) Methode de traitement de la douleur
MX2022011240A (es) Azálidos de urea inmunomoduladores.
WO2008006236A3 (fr) Composés de rafraîchissement à base de benzimidazole
DOP2004000850A (es) Triazoles sustituidos con biarilo como bloqueantes del canal de sodio
MXPA05008190A (es) Derivado de oligosacarido.
WO2023217800A3 (fr) Compositions glycosylées et procédés d'utilisation
WO2020176610A8 (fr) Procédé de traitement d'un myélome multiple
BRPI0507837A (pt) métodos e composições para a administração intravenosa de compostos relacionados a inibidores de bomba de prótons
SE0201881D0 (sv) Novel compounds, their use, and preparation
TH77894B (th) "เฮพทา-,ออคทา-และโนนาเพนไทด์ ที่มีการออกฤทธิ์ เชิงแอนทีแองกิโอจีนิค"

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application